Agilent Technologies, Inc. $A Stock Holdings Increased by Amundi

Key Points

• Amundi Investments has increased its stake in Agilent Technologies by 0.8%, owning a total of 1,096,994 shares valued at approximately $120.3 million.
• Analyst opinions are mixed, with target price adjustments ranging from $128 to $150, and an overall rating of "Moderate Buy" for Agilent Technologies.
• Agilent reported quarterly earnings of $1.37 EPS, matching estimates, and its revenue of $1.74 billion exceeded analyst expectations by about $70 million.

Amundi increased its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 0.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,096,994 shares of the medical research company's stock after buying an additional 8,710 shares during the period. Amundi owned about 0.38% of Agilent Technologies worth $120,307,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of A. Ancora Advisors LLC raised its stake in Agilent Technologies by 33.6% during the first quarter. Ancora Advisors LLC now owns 19,063 shares of the medical research company's stock valued at $2,230,000 after buying an additional 4,791 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Agilent Technologies by 17.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 257,278 shares of the medical research company's stock worth $30,096,000 after purchasing an additional 38,784 shares during the period. Generation Investment Management LLP increased its stake in Agilent Technologies by 19.8% during the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after purchasing an additional 824,243 shares during the last quarter. Federation des caisses Desjardins du Quebec raised its holdings in shares of Agilent Technologies by 5.5% during the first quarter. Federation des caisses Desjardins du Quebec now owns 20,656 shares of the medical research company's stock worth $2,416,000 after purchasing an additional 1,085 shares during the period. Finally, Dark Forest Capital Management LP raised its holdings in shares of Agilent Technologies by 918.8% during the first quarter. Dark Forest Capital Management LP now owns 38,003 shares of the medical research company's stock worth $4,446,000 after purchasing an additional 34,273 shares during the period.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Analyst Upgrades and Downgrades

Several research firms have recently commented on A. UBS Group decreased their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. JPMorgan Chase & Co. reduced their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Leerink Partners raised their target price on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. TD Cowen boosted their target price on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Finally, Evercore ISI decreased their target price on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a research report on Thursday, August 28th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and a consensus price target of $139.25.

Agilent Technologies Stock Performance

Shares of NYSE A traded up $2.76 during midday trading on Thursday, reaching $126.88. 1,474,116 shares of the company traded hands, compared to its average volume of 1,662,463. The company has a market cap of $35.97 billion, a price-to-earnings ratio of 29.78, a PEG ratio of 3.86 and a beta of 1.24. The stock has a 50-day moving average price of $119.72 and a 200 day moving average price of $116.07. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter last year, the company earned $1.32 EPS. Agilent Technologies's quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.